Module

Incorporating New Agents in Advanced Breast Cancer

Source: Breast Cancer Annual Update 2005

Incorporating New Agents in Advanced Breast Cancer


Program Director: Clifford A. Hudis, MD

Faculty:

  • Bryan Schneider, MD
  • George W. Sledge, Jr., MD

CME CREDIT INFORMATION

Release Date: 10/11/05

Expiration Date: 10/10/06


Physicians: maximum of 1 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.1 Nursing CE credits

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe novel targeted and cytotoxic agents for breast cancer

  • Review results of recent studies of trastuzumab and bevacizumab in advanced breast cancer

  • Evaluate relative efficacy and safety of novel agents in advanced breast cancer


Content includes:

  • Agents That Target HER-2
  • Agents That Target HER-2:Trastuzumab
  • Agents That Target HER-2: Lapatinib (GW572016)
  • Agents Directed at Tumor Angiogenesis: Bevacizumab
  • Agents Directed at Tumor Angiogenesis: SU011248
  • Agents Directed at Tumor Angiogenesis: ZD6474
  • Agents Directed at Mammalian Target of Rapamycin (mTOR)
  • Agents That Target Microtubules: New Formulations of an Old Target
  • Agents That Target Microtubules: Ixabepilone (BMS-247550)
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.